Development of anti-HIV-1 peptides based on the concept of the discrimination of helical surfaces
基于螺旋面区分概念的抗HIV-1肽的开发
基本信息
- 批准号:15390037
- 负责人:
- 金额:$ 7.55万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (B)
- 财政年份:2003
- 资助国家:日本
- 起止时间:2003 至 2005
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
We have been confronted with epidemic threat of infectious disease caused by emerging mortal viruses including HIV-1 and SARS-CoV. A general strategy for development of anti-viral drugs targeting at a common infection machinery has been desired, which provides new methodologies for the prevention and treatment of other newly emerging viruses. Among several infection machineries, membranes fusion steps between viruses and target cells are potential targets. A wide variety of viruses are presumed to establish their cell/virus membranes fusion by formation of supramolecular structures of Env proteins of the viruses. For example, membrane fusion of HIV-1 and target cells has been well known to be mediated by formation of a six-helix bundle resulting from the coiled-coil interaction between highly α-helical N-(or heptad repeat 1:HR1) and C (or heptad repeat 2:HR2)-region in the extracellular domain of gp41 (HIV-1 Env protein). And compounds inhibiting the formation of the six-helix bundle s … More tructure in the HIV-1 infection step are well known to work as an anti-HIV-1 drug. We have remodeled the α-helical C-region (HR2)-derived peptides to develop an efficient anti-HIV-1 peptide and found that incorporation of replacement by artificial heptad sequence, X-EE-XX-KK (X=amino acid residues responsible for the interaction with N-(or HR1) region ; E=Glu ; K=Lys), into the C-region of gp41 allowed the remodeled peptides with enhanced α-helicity to exhibit high anti-HIV-1 activity. On the basis of development of this highly effective anti-HIV-1 peptide, we expected that this remodeling strategy, (referred to as X-EE-XX-KK concept), would be widely applicable to other virus using fusion machinery similar to gp41 of HIV-1. Spike (S) protein (Env protein) of SARS-CoV is supposed to be involved in the fusion process in a way to similar to gp41. We applied the same strategy using the X-EE-XX-KK concept to potential α-helical sequence (HR2 region) of the S protein, and found the designed peptides exhibit strong anti-SARS-CoV activity. Less
人类正面临着由HIV-1和SARS-CoV等致命病毒引起的传染病流行的威胁。人们一直希望开发一种针对常见感染机制的抗病毒药物的一般策略,这为预防和治疗其他新出现的病毒提供了新的方法。在多种感染机制中,病毒与靶细胞之间的膜融合步骤是潜在的靶点。推测多种病毒通过形成病毒Env蛋白的超分子结构来建立其细胞/病毒膜融合。例如,众所周知,HIV-1和靶细胞的膜融合是由gp 41(HIV-1 Env蛋白)胞外结构域中高度α-螺旋N-(或七肽重复序列1:HR 1)和C(或七肽重复序列2:HR 2)-区之间的卷曲螺旋相互作用产生的六螺旋束的形成介导的。以及抑制六螺旋束形成的化合物 ...更多信息 众所周知,在HIV-1感染步骤中的结构作为抗HIV-1药物起作用。我们改造了α-螺旋C-区(HR 2)衍生肽,以开发有效的抗HIV-1肽,并发现用人工七肽序列X-EE-XX-KK置换(X=负责与N-(或HR 1)区相互作用的氨基酸残基; E=Glu ; K=Lys)插入gp 41的C-区,使得具有增强的α-螺旋度的重构肽表现出高的抗HIV-1活性。在开发这种高效抗HIV-1肽的基础上,我们预期这种重塑策略(称为X-EE-XX-KK概念)将广泛适用于使用类似于HIV-1的gp 41的融合机制的其他病毒。SARS-CoV的刺突蛋白(S)(Env蛋白)被认为以类似于gp 41的方式参与融合过程。我们采用同样的策略,使用X-EE-XX-KK的概念,潜在的α-螺旋序列(HR 2区)的S蛋白,并发现所设计的肽显示出较强的抗SARS-CoV活性。少
项目成果
期刊论文数量(65)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Akira Otaka et al.: "Application of Samarium Diiodide (SmI_2)-induced Reduction of γ-Acetoxy-α,β-enoates with α-Specific Kinetic Electrophilic Trapping for the Synthesis of Amino Acid Derivatives"Chem.Commun.. 1834-1835 (2003)
Akira Otaka 等人:“应用二碘化钐 (SmI_2) 诱导的 γ-乙酰氧基-α,β-烯酸酯还原与 α-特异性动力学亲电捕获来合成氨基酸衍生物”Chem.Commun. 1834-1835 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Hirokazu Tamamura et al.: "Enhancement of the T140-based Pharmacophores Leads to the Development of More Potent and Bio-stable CXCR4 Antagonists"Org.Biomol.Chem.. 1. 3663-3669 (2003)
Hirokazu Tamamura 等人:“基于 T140 的药效团的增强导致了更有效和生物稳定的 CXCR4 拮抗剂的开发”Org.Biomol.Chem.. 1. 3663-3669 (2003)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Synthesis of Potent β-Secretase Inhibitors Containing a Hydroxyethylamine Dipeptide Isostere and Their Structure-activity Relationship Studies
含羟乙胺二肽等排体的强效β-分泌酶抑制剂的合成及其构效关系研究
- DOI:
- 发表时间:2003
- 期刊:
- 影响因子:0
- 作者:H.Tamamura;N.Yamamoto;A.Otaka;Akira Otaka et al.;Akira Otaka et al.;Akira Otaka et al.;H.Tamamura;A.Otaka;H.Tamamura
- 通讯作者:H.Tamamura
Akira Otaka et al.: "SmI_2-Mediated Reduction of γ,γ-Difluoro-α,β-enoates with Application to the Synthesis of Functionalized (Z)-Fluoroalkene Type Dipeptide Isosteres"J.Org.Chem.. 69. 1634-1645 (2004)
Akira Otaka 等人:“SmI_2 介导的 γ,γ-二氟-α,β-烯酸酯还原及其在功能化 (Z)-氟烯烃型二肽等排体合成中的应用”J.Org.Chem.. 69. 1634- 1645 (2004)
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Synthesis of potent CXCR4 inhibitors possessing low cytotoxicity and improved biostability based on T140 derivatives.
- DOI:10.1039/b306473p
- 发表时间:2003-10
- 期刊:
- 影响因子:3.2
- 作者:H. Tamamura;K. Hiramatsu;S. Kusano;S. Terakubo;N. Yamamoto;J. Trent;Zixuan Wang;S. Peiper;H. Nakashima;A. Otaka;N. Fujii
- 通讯作者:H. Tamamura;K. Hiramatsu;S. Kusano;S. Terakubo;N. Yamamoto;J. Trent;Zixuan Wang;S. Peiper;H. Nakashima;A. Otaka;N. Fujii
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
OTAKA Akira其他文献
OTAKA Akira的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('OTAKA Akira', 18)}}的其他基金
Development of fluorescence probe for visualization of in-cell methylation events
开发用于细胞内甲基化事件可视化的荧光探针
- 批准号:
17K19492 - 财政年份:2017
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
Development of methods for modification of proteins with its application to protein drugs
蛋白质修饰方法的开发及其在蛋白质药物中的应用
- 批准号:
16H02611 - 财政年份:2016
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (A)
Synthetic Study on Semi-synthetic Antibody
半合成抗体的合成研究
- 批准号:
15K14979 - 财政年份:2015
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of highly efficient labelling reagents for protein
高效蛋白质标记试剂的开发
- 批准号:
25670058 - 财政年份:2013
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of synthetic platoform of proteins
蛋白质合成平台的开发
- 批准号:
24390026 - 财政年份:2012
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Development of methodology forchemical synthesis of proteins based on kinetically controlled peptide bond formation
基于动力学控制肽键形成的蛋白质化学合成方法学的发展
- 批准号:
23659055 - 财政年份:2011
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Challenging Exploratory Research
Development of methodologies for catalytic decomposition of proteins
蛋白质催化分解方法的开发
- 批准号:
21390031 - 财政年份:2009
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Davelopment of methodology for the preparation of membrane proteins
膜蛋白制备方法学的发展
- 批准号:
18390006 - 财政年份:2006
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Synthesis of Fluoroalkene Dipeptide Isosteres Using Organocopper Reagents
使用有机铜试剂合成氟代烯烃二肽等排体
- 批准号:
13672210 - 财政年份:2001
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Synthesis of secondary difluoromethylphosphonate-contaning amino acid and its biological examination
二氟甲基膦酸仲氨基酸的合成及其生物学检测
- 批准号:
10671988 - 财政年份:1998
- 资助金额:
$ 7.55万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似国自然基金
170 helix调控凝血因子IXa活性的作用机制研究
- 批准号:82370138
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
CDNF蛋白二级结构中的关键α-Helix对其多巴胺能神经营养活性的影响
- 批准号:81701246
- 批准年份:2017
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
修饰SP-B a-helix 改善ALI时SP功能的研究
- 批准号:81471865
- 批准年份:2014
- 资助金额:72.0 万元
- 项目类别:面上项目
Basic helix-loop-helix(bHLH)蛋白在光信号以及油菜素甾醇调控拟南芥开花过程中的作用
- 批准号:31200216
- 批准年份:2012
- 资助金额:22.0 万元
- 项目类别:青年科学基金项目
腰带长体茧蜂胚胎表面Helix pomatia lectin结合蛋白保护其逃避寄主血细胞包囊反应的机制研究
- 批准号:30971964
- 批准年份:2009
- 资助金额:36.0 万元
- 项目类别:面上项目
相似海外基金
Intrinsically Disordered to α-Helix Transition of the IM30 Protein Structure (R01)
IM30 蛋白质结构 (R01) 本质上无序到 α 螺旋转变
- 批准号:
518273526 - 财政年份:
- 资助金额:
$ 7.55万 - 项目类别:
Collaborative Research Centres